GlassScriptPhysician profile
Philip Mataverde
NPI 1992996458
$3,194.41
in general payments reported to CMS, 2019-2025
11 companies · $871 in 2025
The $871 reported for 2025 was more than what a typical Sleep Medicine (Internal Medicine) provider received nationally (typical 2025 total: $447).
See the full distribution for Sleep Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.98 · 2020: $27.00 · 2021: $396 · 2022: $404 · 2023: $599 · 2024: $844 · 2025: $871.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,212 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,212.13 |
| Education | $102.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $1,145.28 | 2019-2025 | Xywav |
| Inspire Medical Systems, INC. | $969.58 | 2022-2025 | Inspire |
| Harmony Biosciences LLC | $464.48 | 2021-2025 | Wakix |
| Axsome Therapeutics, INC. | $358.38 | 2022-2025 | Sunosi |
| Avadel Cns Pharmaceuticals, LLC | $114.63 | 2024-2025 | Lumryz |
| Merck Sharp & Dohme LLC | $40.86 | 2021 | |
| Zoll Respicardia, INC. | $28.93 | 2025 | Remede System |
| Arbor Pharmaceuticals, INC. | $19.33 | 2021 | |
| Idorsia Pharmaceuticals US INC | $18.86 | 2024 | Quviviq |
| Emd Serono, INC. | $17.12 | 2021 | |
| Acadia Pharmaceuticals INC | $16.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Mataverde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.